Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

After obtaining formal institutional review board approval, the charts of 441 patients from 1996 to 2005 receiving low-dose-rate brachytherapy for prostate ... to offer androgen ablation was ...

A report into recurrent prostate cancer by Figg et al ... time to PSA progression seems to occur after two courses of androgen ablation, which might correspond to the time for the evolution ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

The ADT protocol also included a luteinizing hormone-releasing hormone agonist and anti-androgen for 6 months ... nearly half (48.24%) from prostate cancer. The PSA level at 9 to 10 weeks after ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...